1. Growth and differentiation factor-15 as a potential prognostic biomarker for status-epilepticus-associated-with-fever: A pilot study
- Author
-
Azusa Maruyama, Hiroto Hongo, Masahiro Nishiyama, Daisaku Toyoshima, Ryojiro Tanaka, Hiroshi Yamaguchi, Yusuke Ishida, Hiroshi Kurosawa, Shoichi Tokumoto, Kandai Nozu, Hiroaki Nagase, and Kazumi Tomioka
- Subjects
Male ,medicine.medical_specialty ,Growth Differentiation Factor 15 ,Adolescent ,Fever ,Status epilepticus ,Seizures, Febrile ,Seizure onset ,Status Epilepticus ,Developmental Neuroscience ,Febrile seizure ,Internal medicine ,Simple febrile seizure ,medicine ,Humans ,Prognostic biomarker ,In patient ,Stage (cooking) ,Child ,business.industry ,Infant ,General Medicine ,Prognosis ,medicine.disease ,Child, Preschool ,embryonic structures ,Pediatrics, Perinatology and Child Health ,Female ,Neurology (clinical) ,medicine.symptom ,business ,Biomarkers - Abstract
Biomarkers predicting poor outcomes of status-epilepticus-associated-with-fever (SEF) at an early stage may contribute to treatment guidance. However, none have been reported thus far. We investigated the dynamics of serum growth and differentiation factor (GDF)-15 after seizure onset in patients with SEF and determined whether GDF-15 can predict poor outcomes, particularly in the first 6 h after seizure onset.We enrolled 37 pediatric patients with SEF and eight patients with simple febrile seizures (SFS) and collected their blood samples within 24 h of seizure onset and eight febrile control patients between March 1, 2017 and September 30, 2020. All patients were aged ≤15 years.In the SEF group, the median post-seizure serum GDF-15 values were 1,065 (6h), 2,720 (6-12 h), and 2,411 (12-24 h) pg/mL. The median serum GDF-15 in the first 6 h was measured in patients with SEF without a significant past medical history (n = 21) and was found to be statistically significantly higher (1,587 pg/mL) than in the febrile control (551 pg/mL) and SFS (411 pg/mL) groups. The median serum GDF-15 was statistically significantly higher in patients with SEF with sequelae (n = 5) and patients with acute encephalopathy with biphasic seizures/reduced diffusion/hemorrhagic shock and encephalopathy syndrome (n = 6) than in patients with SEF without sequelae (n = 16) (15,898 vs 756 pg/mL) and patients with prolonged FS (n = 15) (9,448 vs 796 pg/mL).This study demonstrates the dynamics of serum GDF-15 in patients with SEF and indicates the potential of GDF-15 as an early predictor of poor outcomes.
- Published
- 2022